These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 39042099)

  • 1. Adjuvant system AS01: from mode of action to effective vaccines.
    Roman F; Burny W; Ceregido MA; Laupèze B; Temmerman ST; Warter L; Coccia M
    Expert Rev Vaccines; 2024; 23(1):715-729. PubMed ID: 39042099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant system AS01: helping to overcome the challenges of modern vaccines.
    Didierlaurent AM; Laupèze B; Di Pasquale A; Hergli N; Collignon C; Garçon N
    Expert Rev Vaccines; 2017 Jan; 16(1):55-63. PubMed ID: 27448771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review.
    Lacaille-Dubois MA
    Phytomedicine; 2019 Jul; 60():152905. PubMed ID: 31182297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells.
    Didierlaurent AM; Collignon C; Bourguignon P; Wouters S; Fierens K; Fochesato M; Dendouga N; Langlet C; Malissen B; Lambrecht BN; Garçon N; Van Mechelen M; Morel S
    J Immunol; 2014 Aug; 193(4):1920-30. PubMed ID: 25024381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems.
    Garçon N; Van Mechelen M
    Expert Rev Vaccines; 2011 Apr; 10(4):471-86. PubMed ID: 21506645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CCR2- and Flt3-Dependent Inflammatory Conventional Type 2 Dendritic Cells Are Necessary for the Induction of Adaptive Immunity by the Human Vaccine Adjuvant System AS01.
    Bosteels C; Fierens K; De Prijck S; Van Moorleghem J; Vanheerswynghels M; De Wolf C; Chalon A; Collignon C; Hammad H; Didierlaurent AM; Lambrecht BN
    Front Immunol; 2020; 11():606805. PubMed ID: 33519816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toll-like receptor 4 signaling in hematopoietic-lineage cells contributes to the enhanced activity of the human vaccine adjuvant AS01.
    Van Maele L; Fougeron D; Cayet D; Chalon A; Piccioli D; Collignon C; Sirard JC; Didierlaurent AM
    Eur J Immunol; 2019 Dec; 49(12):2134-2145. PubMed ID: 31489613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
    Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
    Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An innate immune signature induced by AS01- or AS03-adjuvanted vaccines predicts the antibody response magnitude and quality consistently over time.
    Tasdighian S; Bechtold V; Essaghir A; Saeys Y; Burny W
    Front Immunol; 2024; 15():1412732. PubMed ID: 39206189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Similarities and differences of chemical compositions and physical and functional properties of adjuvant system 01 and army liposome formulation with QS21.
    Alving CR; Rao M; Matyas GR
    Front Immunol; 2023; 14():1102524. PubMed ID: 36761767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant Systems for vaccines: 13 years of post-licensure experience in diverse populations have progressed the way adjuvanted vaccine safety is investigated and understood.
    Laupèze B; Hervé C; Di Pasquale A; Tavares Da Silva F
    Vaccine; 2019 Sep; 37(38):5670-5680. PubMed ID: 31420171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013.
    Genito CJ; Beck Z; Phares TW; Kalle F; Limbach KJ; Stefaniak ME; Patterson NB; Bergmann-Leitner ES; Waters NC; Matyas GR; Alving CR; Dutta S
    Vaccine; 2017 Jul; 35(31):3865-3874. PubMed ID: 28596090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of Modeling Approaches to Explore Vaccine Adjuvant Mode-of-Action.
    Buckley PR; Alden K; Coccia M; Chalon A; Collignon C; Temmerman ST; Didierlaurent AM; van der Most R; Timmis J; Andersen CA; Coles MC
    Front Immunol; 2019; 10():2150. PubMed ID: 31572370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination.
    Leroux-Roels G; Van Belle P; Vandepapeliere P; Horsmans Y; Janssens M; Carletti I; Garçon N; Wettendorff M; Van Mechelen M
    Vaccine; 2015 Feb; 33(8):1084-91. PubMed ID: 25444781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant-Associated Peripheral Blood mRNA Profiles and Kinetics Induced by the Adjuvanted Recombinant Protein Candidate Tuberculosis Vaccine M72/AS01 in Bacillus Calmette-Guérin-Vaccinated Adults.
    van den Berg RA; De Mot L; Leroux-Roels G; Bechtold V; Clement F; Coccia M; Jongert E; Evans TG; Gillard P; van der Most RG
    Front Immunol; 2018; 9():564. PubMed ID: 29632533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A two-dose optimum for recombinant S1 protein-based COVID-19 vaccination.
    Hu Z; Chen JP; Xu JC; Chen ZY; Qu R; Zhang L; Yao W; Wu J; Yang H; Lowrie DB; Liu Y; Fan XY
    Virology; 2022 Jan; 566():56-59. PubMed ID: 34864488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Lymphatic Immune Response Induced by the Adjuvant AS01: A Comparison of Intramuscular and Subcutaneous Immunization Routes.
    Neeland MR; Shi W; Collignon C; Taubenheim N; Meeusen EN; Didierlaurent AM; de Veer MJ
    J Immunol; 2016 Oct; 197(7):2704-14. PubMed ID: 27549170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity.
    Coccia M; Collignon C; Hervé C; Chalon A; Welsby I; Detienne S; van Helden MJ; Dutta S; Genito CJ; Waters NC; Deun KV; Smilde AK; Berg RAVD; Franco D; Bourguignon P; Morel S; Garçon N; Lambrecht BN; Goriely S; Most RV; Didierlaurent AM
    NPJ Vaccines; 2017; 2():25. PubMed ID: 29263880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlates of adjuvanticity: A review on adjuvants in licensed vaccines.
    Del Giudice G; Rappuoli R; Didierlaurent AM
    Semin Immunol; 2018 Oct; 39():14-21. PubMed ID: 29801750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative preclinical evaluation of AS01 versus other Adjuvant Systems in a candidate herpes zoster glycoprotein E subunit vaccine.
    Fochesato M; Dendouga N; Boxus M
    Hum Vaccin Immunother; 2016 Aug; 12(8):2092-2095. PubMed ID: 26933767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.